{
  "docId": "019de076-6120-7265-9083-1f4de3ff0bf7",
  "docSlug": "b6cd6d5e2a349d701bc6db22946ed621",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 52 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 52,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "Includes detailed clinical trial design, cohort definitions, and study objectives.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-6120-7265-9083-1f4de3ff0bf7/28",
  "deckHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7",
  "deckJsonHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7.json",
  "deckAnchorHref": "/decks/019de076-6120-7265-9083-1f4de3ff0bf7#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.22,
        "w": 0.66,
        "x": 0.26,
        "y": 0.66
      },
      "kind": "list",
      "text": "Phase 2 cohorts were designed to support potential registration in ROS1-positive NSCLC; Primary Objective: ORR; Secondary Objectives: efficacy measures, safety, PK profile.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2ad72b5-ba0e-49f8-841d-ad39e433b76b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.07,
        "y": 0.89
      },
      "kind": "source-note",
      "text": "Approximate cohort size, subject to change; Either crizotinib or entrectinib; Platinum-based chemotherapy; With initial TKI; Includes NSCLC; I-O: Immunotherapy; QD: Once daily; RP2D: Recommended Phase 2 Dose; TKI: Tyrosine Kinase Inhibitor.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e28d5c9-ebc2-4a73-a191-622b13223668",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.85,
        "x": 0.07,
        "y": 0.26
      },
      "kind": "table",
      "text": "Phase 1 and Phase 2 cohort details including N, tumor type, treatment status, and prior therapy.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "392dddcc-180b-43f3-bfe3-693fc07f283d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "ARROS-1 First-in-Human Phase 1/2 Clinical Trial of NVL-520 in Advanced ROS1-Positive NSCLC and Other Solid Tumors (NCT05118789)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "072c469d-5f04-4ce1-810f-e21a635915b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "title",
      "text": "Phase 2 ongoing with global enrollment planned across sites in North America, Europe, Asia and Australia",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f425ded7-d3b7-4d17-8124-ddb8674fd7fb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "4d8b5cc1-2bc6-4515-ba79-9706ebd79db8",
      "evidence": "components include table/data",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}